2. All-trans retinoic acid in the treatment of acute promyelocytic leukemia

Internal Medicine

Volumn 46, Issue 2, 2007, Pages 91-94

  Asou, Norio ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute promyelocytic leukemia; Differentiation therapy; Molecular targeted therapy; Retinoic acid syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CCAAT ENHANCER BINDING PROTEIN; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TAMIBAROTENE;

ARTICLE; CANCER CELL; CANCER MORTALITY; CANCER RELAPSE; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; MOLECULAR MECHANICS; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; RECEPTOR BINDING; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECURRENCE; REMISSION INDUCTION; TRETINOIN;

EID: 33846542442     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.1780     Document Type: Article

References (8)

1. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 17: 1454-1463, 2003.
2. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
3. Asou N. Lessons learned from differentiation therapy with all-trans retinoic acid in the JALSG APL studies. Rinsho Ketsueki 45: 115-124, 2004.
4. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 85: 1202-1206, 1995.
5. Asou N, Adachi K, Tamura U, et al. Acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 48 Suppl 1: S65-S71, 2001.
6. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 16: 78-85, 1998.
7. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
8. Asou N. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia. Internal Med 44: 775-776, 2005.